Janet discusses the growing hospital at home (H@H) care movement that ramped up during COVID. She reflects on how hospitals will adjust to this new trend and its financial sustainability, as well as how it fits into the value-based care landscape. Finally, she presents opportunities for pharmaceutical companies to engage in this new care delivery model.

Kris discusses CMS’s new site-neutrality payment policy, which is a major focus for AHIP. While this may be a win for payers, there are considerable risks for hospital systems, and it may have long term impacts on consolidation trends. Impacts on specialty pharmacy and site of care strategies will change how pharmaceutical companies need to convey their value story.

Sejal describes novel approaches to the long-standing problem of health care system fragmentation and transitions of care. New partnerships and disruptors like CVS and Signify Health, Good Rx, and Amazon are attempting to solve for fragmentation as it can lead to poor medication adherence and outcomes. Pharmaceutical companies can also be a leader in this space. Sejal provides recommendations on how manufacturers can support payers and improve the transition planning process.

Barbara dives deeper into rural hospital closures and the growing rural health care crisis. She discusses new payer policy approaches as well as efforts in the virtual care and digital tool space. She concludes her article with insightful suggestions for pharmaceutical companies to partner with payers in addressing this growing health care gap.